Mochida Pharmaceutical Co (FRA:MFY) Total Liabilities: €231.1 Mil (As of Mar. 2026)


FRA:MFY Mochida Pharmaceutical Co Ltd FRA:MFY
69 GF Score
Price €16.80
GF Value €19.40
! 4 Warning Signs
View Full Analysis

What is Mochida Pharmaceutical Co Total Liabilities?

Mochida Pharmaceutical Co FRA:MFY +1.20% 69 Total Liabilities is €231.1 Mil as of Mar. 2026. GuruFocus rates FRA:MFY with a GF Score™ of 69/100 and a GF Value™ of €19.40. The stock has 4 warning signs investors should review.

Mochida Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2026 was €231.1 Mil.

Mochida Pharmaceutical Co's quarterly Total Liabilities increased from Sep. 2025 (€175.84 Mil) to Dec. 2025 (€245.33 Mil) but then declined from Dec. 2025 (€245.33 Mil) to Mar. 2026 (€231.11 Mil).

Mochida Pharmaceutical Co's annual Total Liabilities declined from Mar. 2024 (€189.35 Mil) to Mar. 2025 (€182.62 Mil) but then increased from Mar. 2025 (€182.62 Mil) to Mar. 2026 (€231.11 Mil).


Mochida Pharmaceutical Co Total Liabilities Historical Data

* Premium members only.

The historical data trend for Mochida Pharmaceutical Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mochida Pharmaceutical Co Total Liabilities Chart

Mochida Pharmaceutical Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 264.15 224.01 189.35 182.62 231.11

Mochida Pharmaceutical Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 182.62 183.57 175.84 245.33 231.11
FRA:MFY
69GF Score
Mochida Pharmaceutical Co Ltd FRA:MFY
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mochida Pharmaceutical Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Mochida Pharmaceutical Co's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=151.182+(54.511+7.223
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+18.19+0)
=231.1

Total Liabilities=Total Assets (A: Mar. 2026 )-Total Equity (A: Mar. 2026 )
=996.03-764.924
=231.1

Mochida Pharmaceutical Co's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=151.182+(54.511+7.223
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+18.19+0)
=231.1

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=996.03-764.924
=231.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of €231.1 Mil mean?
Mochida Pharmaceutical Co (FRA:MFY) has a Total Liabilities of €231.1 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Mochida Pharmaceutical Co and its competitors.
Is Mochida Pharmaceutical Co's Total Liabilities too high?
Mochida Pharmaceutical Co's current Total Liabilities is €231.1 Mil. Overall, Mochida Pharmaceutical Co has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Mochida Pharmaceutical Co's Total Liabilities compare to ZTS and UTHR?
Mochida Pharmaceutical Co's Total Liabilities of €231.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Mochida Pharmaceutical Co and its competitors. Mochida Pharmaceutical Co's current Total Liabilities is €231.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mochida Pharmaceutical Co stock overvalued right now?
Mochida Pharmaceutical Co (FRA:MFY) has a current Total Liabilities of €231.1 Mil. The stock's GF Value™ is €19.40, compared to a current price of €16.80 — trading 13.4% below its estimated fair value. The current Total Liabilities is €231.1 Mil. Mochida Pharmaceutical Co's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Mochida Pharmaceutical Co (FRA:MFY), the current Total Liabilities is €231.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Mochida Pharmaceutical Co (FRA:MFY) Overvalued in 2026?

Based on GuruFocus' analysis, Mochida Pharmaceutical Co stock appears to be undervalued. The current stock price of €16.80 is trading 13.4% below its estimated GF Value™ of €19.40.

Key valuation signals for FRA:MFY:

  • Total Liabilities: €231.1 Mil
  • GF Value™: €19.40 vs. price of €16.80 (13.4% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the FRA:MFY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Mochida Pharmaceutical Co Business Description

Other Exchanges 4534:Japan
Address 1-1 Ichigayahonmuracho, Shinjuku-ku, Tokyo, JPN, 162-0845
Mochida Pharmaceutical Co Ltd is a major drug manufacturing company that operates in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. The company's pharmaceuticals business aims to develop and market a broad spectrum of innovative new drugs. One of Mochida's main objectives is to maximize the business performance of its drugs after they are developed and released. The company also creates skin care products for the general public, and these are supplied through pharmacies, drugstores, and mail-order sales.
69GF Score

Get the complete analysis for FRA:MFY

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€16.80
Price
€19.40
GF Value